Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. - Trial NCT06350123
Access comprehensive clinical trial information for NCT06350123 through Pure Global AI's free database. This Phase 2 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
Interventional
drug
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 2
May 01, 2024
Jan 13, 2026
Primary Outcome
Relative change in UACR from baseline to Week 12
Summary
The purpose of the study is to evaluate the efficacy, safety and tolerability of
 balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney
 disease (CKD) and albuminuria. This study will evaluate the effect of the
 balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with
 dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an
 optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06350123
Non-Device Trial